ReviewMikrochimica acta2025
An analytical review of the therapeutic application of recent trends in MIL-based delivery systems in cancer therapy.
Review in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- pH-responsive Ni-MOF based nanocarriers with folic acid targeting for enhanced chemotherapeutic efficacy in breast cancer.RSC advances · 2026Article
- The Application of Metal-Organic Frameworks as Drug Delivery Systems: From the Perspective of Molecular Dynamics Simulations.MedComm · 2026Review
- Design of a dual-responsive system based on ferrocene and porous FeDiscover nano · 2025Article
- Climate friendly MOFs synthesis for drug delivery systems by integrating AI, intelligent manufacturing, and quantum solutions in industry 6.0 sustainable approach.Toxicology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MILs (Materials Institute Lavoisier), as nanocarriers based on metal-organic frameworks (MOFs), are one of the most advanced drug delivery vehicles that are now a major part of cancer treatment research. This review article highlights the key features and components of MIL nanocarriers for the development and improvement of these nanocarriers for drug delivery. Surface coatings are one of the key components of MIL nanocarriers, which play the role of stabilizing the nanocarrier, pH-dependent drug release, increasing the half-life of the drug, and targeting the carrier. MIL nanocarriers have been synthesized mainly by thermal and hydrothermal methods due to their single-step nature and the ability to produce individual crystals with tunable sizes. According to the data available in the literature, MIL-53 and MIL-101 are the best MILs for drug delivery. These MILs have a high ability to release drugs under acidic conditions, indicating their high efficiency compared to other MILs. In addition to drugs, these nanocarriers can also carry fluorescent, photothermal, and photodynamic agents. These agents allow the MIL nanocarriers to benefit from the therapeutic potential of photothermal and photodynamic agents in addition to the therapeutic capacity of the drug. Furthermore, the fluorescent active ingredient gives these nanocarriers a further tracking capability in addition to the inherent tracking capability of MRI. Therefore, MIL nanocarriers as theranostic carriers have the potential to revolutionize both drug delivery and imaging.
Indexed as
Identifiers
39821354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.